Dipentum

Ulcerative Colitis
Treatment
2 FDA approvals
15 Active Studies for Dipentum

What is Dipentum

OlsalazineThe Generic name of this drug
Treatment SummaryOlsalazine is a medication used to reduce inflammation in the intestines. It is derived from salicylic acid and is converted by bacteria in the colon into mesalamine, which works to reduce inflammation in patients with inflammatory bowel disease and ulcerative colitis.
Dipentumis the brand name
Dipentum Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Dipentum
Olsalazine
1990
5

Approved as Treatment by the FDA

Olsalazine, also known as Dipentum, is approved by the FDA for 2 uses which include Ulcerative Colitis and Ulcerative Colitis .
Ulcerative Colitis
Helps manage Ulcerative Colitis
Ulcerative Colitis
Helps manage Ulcerative Colitis

Effectiveness

How Dipentum Affects PatientsOlsalazine is a drug used to treat Inflammatory Bowel Disease and Ulcerative Colitis, both of which cause inflammation, frequent diarrhea, rectal bleeding, and abdominal pain. Olsalazine works by delivering a special form of a medicine (mesalazine or 5-aminosalicylic acid) to the large intestine, where it can reduce the inflammation and symptoms.
How Dipentum works in the bodyOlsalazine is taken orally and is turned into mesalamine, which helps treat ulcerative colitis. The exact way it works is still unknown, but it seems to work on the site of the inflammation, not throughout the body. Mesalamine may help reduce inflammation by blocking a type of enzyme that produces substances that can cause inflammation.

When to interrupt dosage

The prescribed dosage of Dipentum is contingent upon the diagnosed condition. The amount of dosage varies, as per the method of delivery (e.g. Capsule, gelatin coated or Oral) indicated in the table beneath.
Condition
Dosage
Administration
Ulcerative Colitis
, 250.0 mg
Oral, , Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral

Warnings

There are 20 known major drug interactions with Dipentum.
Common Dipentum Drug Interactions
Drug Name
Risk Level
Description
Macimorelin
Major
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Olsalazine.
Methotrexate
Major
The serum concentration of Methotrexate can be increased when it is combined with Olsalazine.
Mifamurtide
Major
The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Olsalazine.
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Olsalazine is combined with Neomycin.
Omacetaxine mepesuccinate
Major
The risk or severity of bleeding can be increased when Olsalazine is combined with Omacetaxine mepesuccinate.
Dipentum Toxicity & Overdose RiskTests have found that giving mice, rats, and dogs a single oral dose of up to 5g/kg, and 2g/kg respectively, is not lethal.

Dipentum Novel Uses: Which Conditions Have a Clinical Trial Featuring Dipentum?

96 active trials are being conducted to assess the efficacy of Dipentum in treating Ulcerative Colitis.
Condition
Clinical Trials
Trial Phases
Ulcerative Colitis
15 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 4, Phase 1

Dipentum Reviews: What are patients saying about Dipentum?

5Patient Review
6/29/2010
Dipentum for Ulcerative Colitis currently Without Symptoms
Dipentum has been by far the best medication I've tried for my ulcerative colitis. It doesn't have any of the nasty side effects that other medications did, and it's helped me more than anything else I've tried.
5Patient Review
12/31/2008
Dipentum for Ulcerative Colitis currently Without Symptoms
This drug has been a life saver for me. I've been taking it for over 12 years to manage my colitis, and it's worked wonders. I was able to get off of steroids thanks to this medication, and I haven't had any flareups since starting it.
5Patient Review
4/11/2011
Dipentum for Ulcerative Colitis currently Without Symptoms
I've been using this medicine for over a decade and it's worked great, but the price has increased three-fold in the last year. If anyone else has experienced this, please let me know.
5Patient Review
11/18/2015
Dipentum for Ulcerated Colon
I've been taking this drug for almost 30 years and it has done wonders for me. However, in the last year or so, the price has skyrocketed. I used to be able to get a three-month supply for $100, but now it costs me nearly $300. And if I didn't have insurance, it would cost me $1,500 per month! I know that other people are experiencing similar problems, and I hope that somebody comes out with a generic soon.
5Patient Review
6/22/2015
Dipentum for Ulcerative Colitis currently Without Symptoms
This medication has been absolutely integral in managing my Ulcerative Colitis. I was shocked and disappointed to learn that the manufacturer has discontinued it; hopefully there will be a replacement available soon.
5Patient Review
12/20/2013
Dipentum for Inflammatory Bowel Disease
This treatment is amazing! I have rectal bleeding with burning pain and bloating and abdominal distention, but when I take Dipentum, I get relief almost immediately. It's my go-to whenever I have a flare-up, and it always does the job for me.
5Patient Review
7/14/2018
Dipentum for Inflammatory Bowel Disease
I've been using this medication for over 30 years now and I can say with certainty that it's never given me any problems. In contrast, I have experienced negative side effects from other medications.
5Patient Review
1/26/2010
Dipentum for Crohn's Disease
Dipentum has been a game changer for me. I've been taking it regularly for 18 years with minimal side effects.
5Patient Review
7/19/2008
Dipentum for Ulcerative Colitis currently Without Symptoms
I've been on this medication for about fifteen years and, in my opinion, it's been working great.
5Patient Review
8/5/2008
Dipentum for Ulcerative Colitis currently Without Symptoms
I've been on dipentum for 11 years and have never experienced any negative side effects. I also had a stroke last year, but that hasn't stopped me from continuing to use this medication with great results.
4.3Patient Review
9/30/2009
Dipentum for Inflammatory Bowel Disease
This treatment has done wonders for my chronic diarrhea and cramping. The only downside is the cost--$250 a month without insurance coverage
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about dipentum

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Dipentum an anti-inflammatory?

"Dipentum is an aminosalicylate, a type of anti-inflammatory drug. It is believed to work by decreasing the production of prostaglandins, which regulates inflammation in the body. This, in turn, decreases inflammation in the intestines, allowing them to heal and preventing flare-ups."

Answered by AI

What is Dipentum used for?

"Dipentum is a drug that is used to treat ulcerative colitis. It is a salicylate anti-inflammatory drug."

Answered by AI

Is Dipentum available?

"Dipentum is not currently available in the United States. Note: There may be illegal online pharmacies selling a generic version of Dipentum. These medications may be counterfeit and potentially unsafe."

Answered by AI

What drug class is Dipentum?

"Dipentum is a 5-Aminosalicylic Acid Derivative."

Answered by AI

Clinical Trials for Dipentum

Image of Victoria Hospital - London Health Sciences Centre in London, Canada.

Vitamin D for Inflammatory Bowel Disease

18 - 85
All Sexes
London, Canada
The aim of this clinical trial is to gain a better understanding of the effect of Vitamin D supplementation on disease activity and overall health. The main questions it aims to answer are: 1. What proportion of IBD patients adhere to Vitamin D supplement recommendations over a 12-month period? 2. Is the ASK-12 Questionnaire valid in measuring adherence among IBD patients? 3. Does the severity of a patient's Crohn's disease effect overall adherence, over a 12-month period? 4. Does the severity of a patient's Ulcerative Colitis disease effect overall adherence, over a 12-month period? 5. Does Vitamin D supplementation affect the health-related Quality of Life for IBD patients? 6. Is 2,000 IU/Day an effective dose to sustain appropriate blood Vitamin D levels among previously Vitamin deficient IBD patients? Participants will: * Take 2000 IU of Vitamin D every day for the next 12 months * Complete 2 surveys, bloodwork and a fecal calprotectin test at the initial, visit, 6 month follow up and 12 month follow up
Phase 1
Waitlist Available
Victoria Hospital - London Health Sciences CentreTerry Ponich, MD
Image of Rubix LS in Lawrence, United States.

Mirikizumab for Inflammatory Bowel Disease

60 - 99
All Sexes
Lawrence, MA
This research study looks at how safe and effective a medicine called Mirikizumab is for treating older adults (aged 60 and above) who have moderate to severe Crohn's disease (CD) or ulcerative colitis (UC). These two conditions, known as inflammatory bowel diseases (IBD), cause inflammation (swelling and irritation) in the digestive tract. Older adults with these conditions often have other health issues and face increased risks and complications, making it challenging for them to use certain treatments. Mirikizumab is already approved by the FDA for adults with IBD, but there's limited information about how well it works specifically for older adults. This study aims to fill that gap by seeing if Mirikizumab can help these patients safely manage their condition. The study plans to enroll around 150 people from various locations across the United States. Everyone participating will receive Mirikizumab according to the standard, FDA-approved guidelines. The main goal is to see how many participants achieve clinical remission, meaning their symptoms significantly improve or disappear, after 24 weeks of treatment. Researchers will also look at whether this remission lasts up to 48 weeks, how well symptoms are controlled without steroids, how treatment affects indicators of inflammation (such as blood tests), and how the participants feel overall based on their own reports. The safety of Mirikizumab will also be closely monitored throughout the study by regularly checking for any side effects. This study hopes to provide clearer information to help older adults with IBD and their doctors make better treatment decisions, ultimately improving health outcomes and quality of life.
Phase 4
Waitlist Available
Rubix LSEli Lilly and Company
Have you considered Dipentum clinical trials? We made a collection of clinical trials featuring Dipentum, we think they might fit your search criteria.Go to Trials
Image of Carolina Digestive Diseases- Site Number : 8400013 in Greenville, United States.

SAR441566 for Ulcerative Colitis

18 - 75
All Sexes
Greenville, NC
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis. This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment. Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants. * The study duration will be up to 59 weeks. * The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm. * The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.
Phase 2
Recruiting
Carolina Digestive Diseases- Site Number : 8400013 (+28 Sites)Sanofi
Image of University of Chicago in Chicago, United States.

Therapy De-escalation for Ulcerative Colitis

18 - 75
All Sexes
Chicago, IL
The goal of this study is to better understand treatment strategies for people with ulcerative colitis (UC). Researchers will compare patients with UC in histologic remission (no evidence of inflammation or active disease on endoscopy and biopsies) who continue to take medical therapy to patients with UC who de-escalate (decrease or discontinue) medical therapy. Both treatment strategies are considered within regular medical practice. Researchers want to find out whether remission can be maintained after de-escalation of therapy. Participants will be: * either be randomly assigned to continue medical therapy or de-escalate medical therapy -OR- be assigned per the participant's preference * clinically managed according to regular medical care * asked to provide blood, stool (poop), and tissue samples for study purposes
Recruiting
Has No Placebo
University of ChicagoDavid T Rubin, MD
Image of University of Pennsylvania in Philadelphia, United States.

Self-Help Interventions for Crohn's Disease

18+
All Sexes
Philadelphia, PA
EMPOWER-IBD aims to identify behavioral interventions to strengthen patients' self-efficacy for self-management as a mechanism to reduce IBD-related disability. This multisite, randomized controlled trial with 16 arms will randomize adults with moderate-to-severe IBD-related disability to a combination of four multimodal behavioral interventions to test their clinical effectiveness in reducing IBD-related disability and improving self-efficacy. The interventions are four existing, publicly available disease-specific self-help resources offered at no cost to the participants: a book, smart app, help center, and peer mentor. Participants will complete online surveys and may engage in virtual focus groups. Participants may receive an honorarium (e-gift card) and/or be entered into a lottery for a giftcards post-survey completion and focus group participation.
Waitlist Available
Has No Placebo
University of Pennsylvania
Have you considered Dipentum clinical trials? We made a collection of clinical trials featuring Dipentum, we think they might fit your search criteria.Go to Trials
Image of Southern California Res. Ctr. /ID# 169659 in Coronado, United States.

Risankizumab for Ulcerative Colitis

16 - 80
All Sexes
Coronado, CA
The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC. This study consists of three sub-studies and a Continuous Treatment Extension (CTE): Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-19 pandemic or due to the geopolitical conflict in Ukraine and surrounding impacted regions. The CTE is an open-label extension for Substudy 3 completers to ensure continuous treatment with risankizumab until such time that risankizumab becomes commercially available and/or the subject can access treatment locally.
Phase 3
Waitlist Available
Southern California Res. Ctr. /ID# 169659 (+77 Sites)ABBVIE INC.AbbVie
Have you considered Dipentum clinical trials? We made a collection of clinical trials featuring Dipentum, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security